Agenus Inc. (NASDAQ:AGEN) Given Average Recommendation of “Hold” by Brokerages

Agenus Inc. (NASDAQ:AGEN) has earned a consensus recommendation of “Hold” from the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued ratings on the stock in the last year is $14.00.

A number of research analysts recently commented on the company. Robert W. Baird boosted their price target on Agenus from $4.00 to $6.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th. HC Wainwright upgraded shares of Agenus from a “neutral” rating to a “buy” rating and set a $25.00 target price on the stock in a research report on Wednesday, June 4th. B. Riley reissued a “buy” rating on shares of Agenus in a research note on Monday, April 21st. Finally, Wall Street Zen upgraded shares of Agenus from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 22nd.

Institutional Investors Weigh In On Agenus

Large investors have recently modified their holdings of the company. B. Riley Financial Inc. bought a new stake in Agenus during the fourth quarter valued at $2,074,000. Siren L.L.C. bought a new stake in shares of Agenus during the 1st quarter valued at about $752,000. AQR Capital Management LLC boosted its position in shares of Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after purchasing an additional 427,604 shares in the last quarter. Gilead Sciences Inc. acquired a new stake in Agenus during the fourth quarter worth approximately $635,000. Finally, Northern Trust Corp increased its holdings in Agenus by 14.8% in the fourth quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company’s stock worth $572,000 after purchasing an additional 26,870 shares in the last quarter. 61.46% of the stock is currently owned by institutional investors and hedge funds.

Agenus Trading Down 2.5%

NASDAQ AGEN opened at $4.70 on Monday. The company has a market capitalization of $128.86 million, a PE ratio of -0.42 and a beta of 1.43. The stock has a 50-day simple moving average of $3.32 and a 200 day simple moving average of $3.03. Agenus has a 12 month low of $1.38 and a 12 month high of $18.74.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.61) by $0.58. The company had revenue of $24.07 million during the quarter, compared to the consensus estimate of $26.38 million. As a group, sell-side analysts predict that Agenus will post -12.55 earnings per share for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.